GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027
Brief: GRI Bio May Offer Up To $250 Million In Securities - SEC Filing
NASDAQ RESUMED AT 09:37 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 07:59 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Gri Bio Announces Reverse Stock Split
Brief: Gri Bio Announces Additional Positive Data From Phase 2A Study In Idiopathic Pulmonary Fibrosis
GRI Bio jumps as experimental lung drug shows promise in mid-stage trial
NASDAQ RESUMED AT 09:37 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing
U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla